Guided Antiplatelet Therapy in Interventional Treatment of Intracranial Aneurysms
Launched by BEIJING TIANTAN HOSPITAL · Apr 21, 2023
Trial Information
Current as of May 10, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients with unruptured intracranial aneurysms who received intracranial stenting,
- • 2. Standard dualantiplatelet therapy for at least 5 days before stent implantation,
- • 3. Patients aged 18-80,
- • 4. on the day of registration patients with a Modified Rankin Scale lower than 2,
- • 5. patients who agree and sign the consent form.
- Exclusion Criteria:
- • 1. Patients with recurrent aneurysms after interventional therapy or clipping therapy,
- • 2. Patients with a history of allergy to aspirin, clopidogrel or ticagrelor,
- • 3. Patients who used tirofiban prophylactically before surgery,
- • 4. Possible active bleeding Patients with high blood pressure, such as symptomatic intracranial hemorrhage or active gastric ulcer; or patients with bleeding tendency or coagulation dysfunction,
- • 5. Any abnormal platelet count (normal value is 100-300 × 10\^9/L),
- • 6. Patients using anticoagulants,
- • 7. Pregnant or lactating women,
- • 8. Suffering from liver disease, kidney disease, congestive heart failure, malignant tumors and other malignant diseases.
About Beijing Tiantan Hospital
Beijing Tiantan Hospital, affiliated with Capital Medical University, is a leading medical institution in China renowned for its expertise in neurology, neurosurgery, and various other specialties. As a prominent clinical trial sponsor, the hospital is committed to advancing medical research and improving patient outcomes through innovative studies. With a focus on high-quality clinical trials, Beijing Tiantan Hospital adheres to rigorous ethical standards and regulatory requirements, fostering collaboration with academic institutions and industry partners to facilitate the development of cutting-edge therapies and interventions. Its state-of-the-art facilities and experienced research team enable the hospital to play a pivotal role in the global medical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Beijing, Beijing, China
Patients applied
Trial Officials
Xinjian Yang, MD
Principal Investigator
Beijing Tiantan Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported